Balumorexton

Balumorexton
Clinical data
Other namesTAK-360; TAK360
Routes of
administration
Oral
Drug classOrexin OX2 receptor antagonist; Wakefulness-promoting agent
Identifiers
  • N-[(6R)-7,7-difluoro-2-[5-fluoro-4-(2,4,6-trifluorophenyl)-1,2-benzoxazol-3-yl]-3-oxo-5,6-dihydropyrrolo[1,2-c]imidazol-6-yl]methanesulfonamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC20H12F6N4O4S
Molar mass518.39 g·mol−1
3D model (JSmol)
  • CS(=O)(=O)N[C@@H]1CN2C(=CN(C2=O)C3=NOC4=C3C(=C(C=C4)F)C5=C(C=C(C=C5F)F)F)C1(F)F
  • InChI=1S/C20H12F6N4O4S/c1-35(32,33)28-13-6-29-14(20(13,25)26)7-30(19(29)31)18-17-12(34-27-18)3-2-9(22)16(17)15-10(23)4-8(21)5-11(15)24/h2-5,7,13,28H,6H2,1H3/t13-/m1/s1
  • Key:QYIMOBVUEGPQSO-CYBMUJFWSA-N

Balumorexton (INNTooltip International Nonproprietary Name; likely developmental code name TAK-360) is a selective orexin OX2 receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia. It is taken orally. The drug is under development by Takeda. As of June 2025, it is in phase 2 clinical trials for both narcolepsy and idiopathic hypersomnia.

See also